Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at TD Cowen

TD Cowen upgraded shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) to a strong-buy rating in a research report sent to investors on Monday morning,Zacks.com reports.

Several other equities research analysts have also recently weighed in on ARWR. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 20th. Citigroup dropped their price target on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a “neutral” rating for the company in a research note on Tuesday, May 13th. Chardan Capital reiterated a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. Finally, Wall Street Zen cut Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, July 18th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Arrowhead Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.71.

Arrowhead Pharmaceuticals Stock Down 1.4%

NASDAQ ARWR opened at $15.70 on Monday. The business has a fifty day moving average price of $16.40 and a two-hundred day moving average price of $16.13. The company has a debt-to-equity ratio of 0.31, a current ratio of 5.15 and a quick ratio of 5.15. Arrowhead Pharmaceuticals has a fifty-two week low of $9.57 and a fifty-two week high of $29.47. The stock has a market capitalization of $2.17 billion, a PE ratio of -11.21, a PEG ratio of 18.72 and a beta of 0.93.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $2.81. The business had revenue of $542.71 million for the quarter, compared to the consensus estimate of $116.27 million. During the same quarter in the previous year, the company earned ($1.02) earnings per share. Equities analysts expect that Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Institutional Trading of Arrowhead Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC increased its holdings in Arrowhead Pharmaceuticals by 297.6% in the first quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,628 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at about $49,000. CWM LLC grew its stake in shares of Arrowhead Pharmaceuticals by 134.3% in the 1st quarter. CWM LLC now owns 4,401 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 2,523 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Arrowhead Pharmaceuticals by 29.5% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,335 shares of the biotechnology company’s stock valued at $84,000 after buying an additional 1,214 shares during the period. Finally, KBC Group NV grew its stake in shares of Arrowhead Pharmaceuticals by 40.8% in the 1st quarter. KBC Group NV now owns 7,356 shares of the biotechnology company’s stock valued at $94,000 after buying an additional 2,132 shares during the period. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.